Neurocrine Biosciences 的 CRENESSITY 是 70 年来第一个新的 CAH 治疗方法，现已获得 FDA 批准。 Neurocrine Biosciences' CRENESSITY, the first new CAH treatment in 70 years, is now FDA-approved.

Neurocrine Biosciences 的 CRENESSITY 是一种治疗经典先天性肾上腺皮质增生症 （CAH） 的新疗法，已获得 FDA 的批准。 Neurocrine Biosciences' CRENESSITY, a new treatment for classic congenital adrenal hyperplasia (CAH), has been approved by the FDA. 该药物是为4岁和4岁以上的人设计的,是70年来对CAH的首次新治疗。 This drug, designed for individuals aged four and older, is the first new treatment for CAH in 70 years. 它可以减少过量的雄激素产生,从而降低葡萄皮质激素剂量. It reduces excess androgen production, allowing for lower doses of glucocorticoids. 根据临床试验,它显示在管理病情方面有重大改进。 Based on clinical trials, it showed significant improvements in managing the condition. CRENESSITY 将在大约一周内上市。 CRENESSITY will be available in about a week. 常见副作用包括疲劳、晕眩和腹部疼痛。 Common side effects include fatigue, dizziness, and abdominal pain.